
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC has demonstrated a promising financial outlook, highlighted by a 95% probability of success for its psilocybin therapy, COMP360, following positive data from the COMP005 trial. The therapy has shown a statistically significant -3.6 point reduction on the MADRS scale, indicating its effectiveness in treating treatment-resistant depression. Additionally, the anticipated low-frequency dosing of COMP360, requiring only 2–4 sessions per year, positions it favorably against existing therapies, potentially increasing patient adherence and enhancing market adoption.
Bears say
Compass Pathways PLC is facing a negative outlook due to increased research and development expenses associated with advancing its COMP360 Phase 3 clinical trials, which exceeded prior estimates and impacted cash reserves, totaling $221.9 million as of June 30. Additionally, competitive pressures could arise if peers in the mental health space generate compelling data, potentially putting further downward pressure on Compass's stock. The company's strategic reorganization has led to decreased general and administrative expenses; however, reliance on a narrow cash position amidst rising costs and market competition raises substantial concerns regarding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares